Sign inJoin waitlistJoin the waitlist

John Kaczmar

Deputy Medical Director, Hollings Clinical Trials Office · Medical University of South Carolina College of Medicine

Credentials: · · · · ·

History

Hollings Clinical Trials Office · Medical University of South Carolina College of Medicine
Present
Hematology & Oncology Division · Medical University of South Carolina College of Medicine
Present
Medical University of South Carolina College of Medicine
Present

Hematology and Medical Oncology
Fox Chase Cancer Center
2014–2017
Hospital
2011–2014
College of Medicine
2006–2010
Cornell University

Research

Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma
Clinical Cancer Research · 2022 · 178 citations
Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma
Cell Reports Medicine · 2021 · 83 citations
Racial and Ethnic Disparities in Travel for Head and Neck Cancer Treatment and the Impact of Travel Distance on Survival
Cancer · 2018 · 68 citations

Evan Graboyes
13 papers · 2 as a fellow
DN
David Neskey
9 papers
Shaun Nguyen
9 papers
Jason Newman
8 papers
Alexandra Kejner
7 papers
AS
Anand Sharma
7 papers
William Albergotti
7 papers
Bhishamjit Chera
5 papers
BN
Brian Nussenbaum
5 papers
Jennifer Harper
5 papers
Judith Skoner
5 papers
Flora Yan
4 papers

Clinical trials

Anti-platelet + Pembro for H&N Tumors
Principal investigator · Completed · Phase 1
Medical University of South Carolina
2018–2024
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2025–2029
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Site PI · Recruiting · Phase 3
ECOG-ACRIN Cancer Research Group
2024–2030
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2029